Roche later made changes to the trial design, although the company said overall results support further testing.

An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Under the terms of the agreement, Roche will pay Dyno Therapeutics $50m upfront, along with additional payments during the ...

Roche revealed early-stage data for a new Alzheimer’s program on Wednesday as it seeks to jump back into a field littered ...

DelveInsight's Neurological Biomarkers Market Insights report provides the current and forecast market analysis, individual leading neurological biomarkers companies' market shares, challenges, ...

Protein Diagnostics MarketAccording to a recent analysis by Future Market Insights (FMI), the global protein diagnostics market is poised for substantial growth over the coming decade, with an ...

Q3 2024 Earnings Call Transcript October 30, 2024 8:30 AM ETCompany ParticipantsStephen Amato - Senior Director of ...

Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing.

ABC News reports a 17.5% increase in asthma-related hospitalization in the three months after Flovent was discontinued and a 24.1% increase in the next three to six months. Other pharma news covers ...